Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1988375 | 0.89 | FFAR2 (0.39) | SMN1; SMN2TSHRKMT2AHTTFFAR2 | |
| SCHEMBL1996083 | 0.86 | GRM5 (0.40) | SMN1; SMN2TSHRKMT2AMEN1RAB9A | |
| SCHEMBL1989681 | 0.86 | TSHR (0.45) | SMN1; SMN2TSHRKMT2AHTTFFAR2 | |
| SCHEMBL1990504 | 0.85 | FFAR2 (0.39) | SMN1; SMN2TSHRKMT2AFFAR2MEN1 | |
| SCHEMBL1990889 | 0.85 | NPC1 (0.37) | SMN1; SMN2TSHRKMT2AHTTALDH1A1 | |
| SCHEMBL1987379 | 0.85 | MEN1 (0.36) | SMN1; SMN2TSHRKMT2AHTTALDH1A1 | |
| SCHEMBL3403687 | 0.82 | CTSD (0.38) | SMN1; SMN2KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL977045 | 0.82 | CACNA2D1 (0.41) | KMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL1990049 | 0.82 | MEN1 (0.45) | SMN1; SMN2TSHRKMT2AFFAR2ALDH1A1 | |
| SCHEMBL1551291 | 0.82 | MEN1 (0.47) | SMN1; SMN2TSHRKMT2AHTTFFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | claimed |
| WO-2010018328-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | C1R, TACR1, C1S | SMN1; SMN2 2797/4885TSHR 795/4885KMT2A 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.